Affiliation:
1. Associate professor, Department of Pathology, Shyam Shah Medical College, Rewa (M.P.).
2. Professor, Department of Pathology, Shyam Shah Medical College, Rewa (M.P.).
3. Professor, Department of Medicine, Shyam Shah Medical College, Rewa (M.P.)
Abstract
Background: Diabetes mellitus (DM) is becoming a global pandemic. The number of people with diabetes in India increased from 26·0 million in
1990 to 65·0 million in 2016. Diabetes mellitus (DM) has been considered as a 'prothrombotic state' with enhanced platelet reactivity. Diabetic
patients have an increased risk of developing micro and macro vascular diseases, and platelets may be involved as putative agents owing to their
altered morphology, function and activation. It is an established fact that the value of glycated hemoglobin (HbA1c), a marker of long-term
glucoregulation, should be kept below 7% in order to reduce the risk of micro and macrovascular complications in Type 2 Diabetes Mellitus
(DMT2) patients. Mean platelet volume (MPV) has been correlated with vascular complications of DMT2. MPV as a marker of platelet size,
function & activation may serve as another potential marker of risk of micro-vascular and macrovascular complications in DMT2 patients.
Aims-To study correlation between MPV, and HbA1c in DMT2 patients.
Methods- Over a period of 24 months, patients aged between 30 to 60 years, diagnosed with DMT2 and subtyped based on American Diabetic
Association Criteria (ADA) as having HbA1c either less than 7% - DMT2 (Controlled group) or with HbA1c more than 7% - DMT2 (Uncontrolled
group) were included in the present study. Non-diabetic patients ('Non Diabetic Group) were included based on their fasting and post prandial
blood glucose levels and served as controls. Venous blood samples were tested for fasting, postprandial and random blood sugar estimation by
GOD-POD method, MPV by automated cell counter and HbA1c by HPLC, within one hour of sampling. Results were statistically tested using
(R) unpaired t Test by SPSS Software (version 22).
Results- Among 236 patients studied, 66 were 'Non-diabetic controls' & 170 were having diabetes (DMT2). Of those having DMT2, 94 patients
belonged to DMT2 (Uncontrolled group) 76 patients belonged to DMT2 (Controlled group). MPV in Non-diabetic group, DMT2 (Controlled
group) and DMT2 (Uncontrolled group) was 10.01 ± 1.12 , 10.76 ± 1.11 and 11.67 ± 1.83 respectively. MPVwas signicantly higher in DMT2
group compared to Non-diabetic group (10.82 ± 1.31 vs 10.01 ± 1.12 , p < 0.0001), MPV was also signicantly higher in DMT2 (Uncontrolled
group) compared to DMT2 (Controlled group) (11.67 ± 1.83 vs. 10.76 ± 1.11 , p < 0.0001).
Conclusion- In the present study Mean Platelet Volume was found to be signicantly higher in Diabetes Mellitus Type 2 patient compared to Nondiabetic patients. Higher MPV also correlated with higher HbA1c, being higher in those with higher HbA1c. It can be concluded that MPV may be
useful as inexpensive surrogate marker of HbA1c in the diagnosis and prognosis of vascular complications of DMT2 patients.
Reference27 articles.
1. India State-Level Disease Burden Initiative Diabetes Collaborators. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health 2018; 6: e1352–62.
2. Abhijeet S, Kaveeshwar, Cornwal J. The current state of diabetes mellitus in India. Australasian Med J. 2014;7(1):45-48.
3. Hekimsoy Z, Payzinb B, Ornek T, Kandogan G. Mean platelet volume in type 2 diabetes patients. J Diabetes Complications. 2004;18:173-6.
4. Pretorius, L., Thomson, G.J.A., Adams, R.C.M. et al. Platelet activity and hypercoagulation in type 2 diabetes. Cardiovasc Diabetol 17, 141 (2018)
5. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009; 119:351-7.